Sistema de Salut de Catalunya
Institut Català de la Salut
[Puyana Ortiz JD] International Health and Cooperation UAB, Barcelona, Spain. [Garcés Rodríguez AC] Morales Meseguer University Hospital, Murcia, Spain. [Aznar ML, Espinosa Pereiro J, Sánchez-Montalvá A] Centre de Salut Internacional i Malalties Transmissibles Drassanes-Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Grupo de Estudio de Micobacterias (GEIM), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), Madrid, Spain. [Campreciós J, Serre Delcor N, Oliveira I, Treviño Maruri B, Ciruelo DP, Salvador F, Bosch-Nicolau P, Molina I] Centre de Salut Internacional i Malalties Transmissibles Drassanes-Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Saborit N, García Salgado G, Broto Cortes C] Centre de Salut Internacional i Malalties Transmissibles Drassanes-Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Barcelona, Spain. [Rodrigo-Pendás JÁ, Torrecilla-Martínez I, Zules-Oña R] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Tórtola Fernández MT] Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-08-30T11:54:54Z
2023-08-30T11:54:54Z
2023-07-19
Latent tuberculosis infection; Toxicity; Tuberculosis screening
Infecció tuberculosa latent; Toxicitat; Cribratge de tuberculosi
Infección tuberculosa latente; Toxicidad; Cribado de tuberculosis
The screening and treatment of latent tuberculosis infection (LTBI) in countries with a low incidence of TB is a key strategy for the elimination of tuberculosis (TB). However, treatment can result in adverse events (AEs) and have poor adherence. This study aimed to describe treatment outcomes and AEs for LTBI patients at two departments in Vall d'Hebron University Hospital in Barcelona, Spain. A retrospective study was conducted on all persons treated for LTBI between January 2018 and December 2020. Variables collected included demographics, the reason for LTBI screening and treatment initiation, AEs related to treatment, and treatment outcome. Out of 261 persons who initiated LTBI treatment, 145 (55.6%) were men, with a median age of 42.1 years. The indications for LTBI screening were household contact of a TB case in 96 (36.8%) persons, immunosuppressive treatment in 84 (32.2%), and recently arrived migrants from a country with high TB incidence in 81 (31.0%). Sixty-three (24.1%) persons presented at least one AE during treatment, and seven (2.7%) required definitive discontinuation of treatment. In the multivariate analysis, AE development was more frequent in those who started LTBI treatment due to immunosuppression. Overall, 226 (86.6%) completed treatment successfully. We concluded that LTBI screening and treatment groups had different risks for adverse events and treatment outcomes. Persons receiving immunosuppressive treatment were at higher risk of developing AEs, and recently arrived immigrants from countries with a high incidence of TB had greater LTFU. A person-centered adherence and AE management plan is recommended.
A.M.L. was supported by a postdoctoral grant “Juan Rodés” (JE21/00027) from the Instituto de Salud Carlos through the Ministry of Economy and Competitiveness, Spain.
Article
Published version
English
Medicaments antituberculosos - Efectes secundaris; Tuberculosi - Tractament; DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Actinomycetales Infections::Mycobacterium Infections::Tuberculosis::Latent Tuberculosis; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents::Antitubercular Agents; Other subheadings::Other subheadings::Other subheadings::/adverse effects; ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones por Actinomycetales::micobacteriosis::tuberculosis::tuberculosis latente; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos::antituberculosos; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
MDPI
Tropical Medicine and Infectious Disease;8(7)
https://doi.org/10.3390/tropicalmed8070373
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
